The Functional and Emotional Benefits of Replenix Power of Three With Resveratrol

Acne Vulgaris Clinical Trial

Official title:

A Randomized, Investigator Blinded, Single Site, Three Arm Clinical Study to Assess the Functional and Emotional Benefits of Replenix Power of Three Cream With Resveratrol , Replenix Power of Three Cream With Resveratrol With Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5%, and Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5%, Utilized to Treat Subjects With Facial Acne Vulgaris

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03563365
• Other study ID #: TPX-PW3-2018-A
• Status: Terminated
• Phase: Phase 4
• Start date: June 4, 2018
• Est. completion date: March 2, 2021

Study information

• Verified date: April 2021
• Source: Yardley Dermatology Associates
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Randomized, Investigator Blinded, Single Site, Three Arm Clinical Study to Assess the Functional and Emotional Benefits of Replenix Power of Three Cream with Resveratrol , Replenix Power of Three Cream with Resveratrol with Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5%, and Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5%, utilized to treat subjects with Facial Acne Vulgaris

Description:

Acne vulgaris is a common skin problem which can be challenging to treat. Enhancing the efficacy and tolerability of treatment regimens can enhance compliance and outcomes thereby potentially decreasing the morbidities associated with acne vulgaris. The present study is designed to assess the ability of Power of 3 with resveratrol to improve efficacy and tolerability of an existing combination acne medication.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 43
• Est. completion date: March 2, 2021
• Est. primary completion date: March 2, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 12 Years to 40 Years

Eligibility

Inclusion Criteria:

1. Healthy male or non pregnant female aged = 12 and = 40 years with a clinical diagnosis of Acne vulgaris

2. On the face, = 20 non-inflammatory lesions (i.e., open and closed comedones) AND < 75 inflammatory lesions (i.e., papules and pustules) AND = 1 nodulocystic lesions (i.e., nodules and cysts).

3. Investigator's Global Assessment (IGA) of acne severity grade 2 or 3

4. Subject must be able to follow study instructions and likely to complete all required visits, as assessed by the Investigator.

5. Subject/Guardian must sign an IRB-approved Informed Consent/Assent/Assent Form including photography consent, and the Authorization for Use and release of Health and Research Study Information (HIPAA) form prior to any study-related procedures being performed

Exclusion Criteria:

1. Presence of any skin condition that would interfere with the diagnosis or assessment of acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid folliculitis, or bacterial folliculitis).

2. Subjects who have acne conglobata, acne fulminans and secondary acne (e.g.:

chloracne and drug induced acne).

3. Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere with diagnosis or assessment of acne vulgaris. Well trimmed moustaches are allowed.

4. History of hypersensitivity or allergy to benzoyl peroxide or adapalene and or any of the study product ingredients.

5. Subjects who have a severe or intense irritation on the face.

6. Use within 6 months prior to baseline (Randomization) of oral retinoids (e.g. Accutane®) or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are allowed).

7. Use for less than 3 months prior to baseline (Randomization) of estrogens or oral contraceptives; use of such therapy is allowed if it will remain constant throughout the study.

8. Use on the face within 1 month prior to baseline (Randomization) or during the study of: 1) cryodestruction or chemodestruction, 2) dermabrasion, 3) photodynamic therapy, 4) acne surgery, 5) intralesional steroids, or 6) x-ray therapy.

9. Use within 1 month prior to baseline (Randomization) of: 1) spironolactone, 2) systemic steroids, 3) systemic antibiotics, 4) systemic treatment for acne vulgaris (other than oralretinoids, which require a 6-month washout), or 5) systemic anti- inflammatory agents.

10. Use within 2 weeks prior to baseline (Randomization) of: 1) topical steroids, 2) topical retinoids, 3) topical acne treatments including over-the-counter preparations, 4) topical anti-inflammatory agents, 5) medicated cleansers or 6) topical antibiotics.

11. Subjects who have had general anesthesia for any reason and patients who have received neuromuscular blocking agents within 14 days prior to study entry (Randomization).

12. Concomitant use of facial product containing glycolic or other acids, masks, washes or soaps containing benzoyl peroxide or salicylic acid, non mild cleansers or moisturizers containing retinol, salicylic or a- or ß-hydroxy acids.

13. Concomitant use of mega-doses of certain vitamins (such as vitamin D and vitamin B12), haloperidol, halogens such as iodide and bromide, lithium, hydantoin and phenobarbital.

14. Facial procedures (chemical or laser peel, microdermabrasion, etc.) within the past 2 weeks or during the study.

15. Concomitant use of tanning booths or sunbathing.

16. A significant medical history of or are currently immunocompromised

17. Have any systemic or dermatologic disease that may affect the evaluation of study results.

18. Have a history of regional enteritis, ulcerative colitis, pseudomembranous colitis or antibiotic-associated colitis.

19. Subjects with clinically significant unstable medical disorders, life-threatening disease, or current malignancies.

Related Conditions & MeSH terms

• Acne Vulgaris

Intervention

Other:
• Replenix Power of 3 Cream with resveratrol
Cosmetic product containing Green Tea Polyphenols, Resveratrol, Caffeine USP, Bisabolol Cucumber extract, Chamomile extract, Rosemary extract, Squalane, Soy Phospholipids

Drug:
• Adapalene and Benzoyl peroxide gel, 0.1%/2.5%
FDA approved topical agent for the treatment of acne

Locations

Country	Name	City	State
United States	Yardley Dermatology Associates, PC	Yardley	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Yardley Dermatology Associates	Topix Pharmaceuticals, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Investigator Global Assessment (IGA)	To assess the change in Acne Vulgaris on a scale of 1 to 4, where 1 represents clear skin and 4 represents severe acne, at each scheduled visit with the use of Replenix Power of three with Resveratrol.	Screening, Baseline, Week 2, Week 4, Week 8, Week 12
Primary	Subject Global Assessment (SGA)	To assess the change in Acne Vulgaris on a scale of 1 to 5, where 1 represents a worsening of acne and 5 represents clearing of acne, at each scheduled visit as compared to baseline with the use of Replenix Power of three with Resveratrol.	Screening, Baseline, Week 2, Week 4, Week 8, Week 12
Primary	Subject Overall Assessment of Tone and Texture (SOATT)	To assess the change on skin tone and texture on a scale of 1 to 7, where 1 represents worse tone and texture and 7 represents better tone and texture, at each scheduled visit with use of Replenix Power of three with Resveratrol.	Screening, Baseline, Week 2, Week 4, Week 8, Week 12
Primary	Investigator Overall Assessment of Tone and Texture (IOATT)	To assess the change on skin tone and texture on a scale of 1 to 7, where 1 represents worse tone and texture and 7 represents better tone and texture, at each scheduled visit with use of Replenix Power of three with Resveratrol.	Screening, Baseline, Week 2, Week 4, Week 8, Week 12
Primary	Subject Assessment of Skin Dysesthesia (SDA)	To assess the change in Dysesthesia on a scale of 1 to 7, where 1 represents no dysesthesia and 7 represents severe dysesthesia, at each scheduled visit with use of Replenix Power of three with Resveratrol.	Screening, Baseline, Week 2, Week 4, Week 8, Week 12
Primary	Subject Quality of Life (SQOL)	To assess the change in Subject Quality of Life on a scale of 1 to 7, where 1 represents better quality of life and 7 represents worse quality of life, at Screening, Baseline and week 12 with use of Replenix Power of three with Resveratrol.	Screening, Baseline, Week 12
Primary	Local Tolerability Assessment	To assess the change in Local Tolerability on a scale of 0 to 3, where 0 represents no tolerability issues and 3 represents severe tolerability issues, at each scheduled visit with use of Replenix Power of three with Resveratrol.	Screening, Baseline, Week 2, Week 4, Week 8, Week 12